- Home
- ISPR vs HURA Comparison
ISPR vs HURA Comparison
Compare ISPR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- HURA
- Stock Information
- Founded
- ISPR 2019
- HURA 2009
- Country
- ISPR United States
- HURA United States
- Employees
- ISPR N/A
- HURA N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- HURA
- Sector
- ISPR Health Care
- HURA
- Exchange
- ISPR Nasdaq
- HURA Nasdaq
- Market Cap
- ISPR 152.0M
- HURA 171.7M
- IPO Year
- ISPR 2023
- HURA N/A
- Fundamental
- Price
- ISPR $2.56
- HURA $2.26
- Analyst Decision
- ISPR Strong Buy
- HURA Strong Buy
- Analyst Count
- ISPR 2
- HURA 2
- Target Price
- ISPR $10.00
- HURA $11.50
- AVG Volume (30 Days)
- ISPR 75.5K
- HURA 401.7K
- Earning Date
- ISPR 05-12-2025
- HURA 08-15-2025
- Dividend Yield
- ISPR N/A
- HURA N/A
- EPS Growth
- ISPR N/A
- HURA N/A
- EPS
- ISPR N/A
- HURA N/A
- Revenue
- ISPR $144,700,345.00
- HURA N/A
- Revenue This Year
- ISPR N/A
- HURA N/A
- Revenue Next Year
- ISPR $35.39
- HURA $69.15
- P/E Ratio
- ISPR N/A
- HURA N/A
- Revenue Growth
- ISPR N/A
- HURA N/A
- 52 Week Low
- ISPR $2.09
- HURA $1.80
- 52 Week High
- ISPR $8.13
- HURA $13.13
- Technical
- Relative Strength Index (RSI)
- ISPR 50.95
- HURA N/A
- Support Level
- ISPR $2.09
- HURA N/A
- Resistance Level
- ISPR $2.56
- HURA N/A
- Average True Range (ATR)
- ISPR 0.22
- HURA 0.00
- MACD
- ISPR 0.00
- HURA 0.00
- Stochastic Oscillator
- ISPR 61.84
- HURA 0.00
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.